Education
About Us
Working with TipRanks
Follow Us
Cencora, Inc. (COR)
:COR
COR Stock Chart & Stats
$368.53
$2.86(1.22%)
At close: 4:00 PM EST
$368.53
$2.86(1.22%)
Day’s Range― - ―
52-Week Range$223.92 - $377.54
Previous CloseN/A
Volume440.68K
Average Volume (3M)1.47M
Market Cap
$71.49B
Enterprise Value$65.77B
Total Cash (Recent Filing)$4.36B
Total Debt (Recent Filing)$7.66B
Price to Earnings (P/E)46.3
Beta0.06
Next Earnings
Feb 04, 2026EPS Estimate
4.07Last Dividend Ex-Date
Nov 14, 2025Dividend Yield0.61%
Share Statistics
EPS (TTM)3.84
Shares Outstanding193,993,440
10 Day Avg. Volume1,680,178
30 Day Avg. Volume1,472,277
Financial Highlights & Ratios
PEG Ratio6.89
Price to Book (P/B)34.69
Price to Sales (P/S)0.19
P/FCF Ratio18.90
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit6.27
Enterprise Value/Ebitda17.76
Forecast
1Y Price Target
$393.78Price Target Upside6.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)17.65
Revenue Forecast (FY)$340.70B
Bulls Say, Bears Say
Bulls Say
Growth In Oncology And GenericsLong-term fundamentals, including exposure to oncology, generics, and biosimilars, remain attractive and are expected to provide meaningful upside.
Price Target IncreaseThe analyst reiterates a Buy rating and raises the price target to $400.
US HC GuidanceThere is likely upside to COR's US HC guide of +9-11%.
Bears Say
FY26 US HC GuidanceManagement will likely set its FY26 US HC growth guide in line with its long-term growth targets of 5-8%, which could disappoint investors expecting a higher consensus of 9%.
Potential Growth DecelerationThe expected guidance for FY26 could pressure shares over the near term due to a potential growth deceleration.
Share Price LimitationsThe lack of upside catalysts in the near term and shares trading near all-time highs suggest shares likely remain range-bound.
Cencora News
COR FAQ
What was Cencora, Inc.’s price range in the past 12 months?
Cencora, Inc. lowest stock price was $223.92 and its highest was $377.54 in the past 12 months.
What is Cencora, Inc.’s market cap?
Cencora, Inc.’s market cap is $71.49B.
When is Cencora, Inc.’s upcoming earnings report date?
Cencora, Inc.’s upcoming earnings report date is Feb 04, 2026 which is in 68 days.
How were Cencora, Inc.’s earnings last quarter?
Cencora, Inc. released its earnings results on Nov 05, 2025. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.787 by $0.053.
Is Cencora, Inc. overvalued?
According to Wall Street analysts Cencora, Inc.’s price is currently Undervalued.
Does Cencora, Inc. pay dividends?
Cencora, Inc. pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.61%. See more information on Cencora, Inc. dividends here
What is Cencora, Inc.’s EPS estimate?
Cencora, Inc.’s EPS estimate is 4.07.
How many shares outstanding does Cencora, Inc. have?
Cencora, Inc. has 193,993,440 shares outstanding.
What happened to Cencora, Inc.’s price movement after its last earnings report?
Cencora, Inc. reported an EPS of $3.84 in its last earnings report, beating expectations of $3.787. Following the earnings report the stock price went up 2.75%.
Which hedge fund is a major shareholder of Cencora, Inc.?
Currently, no hedge funds are holding shares in COR
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$393.78 (6.85% Upside)
$393.78 (6.85% Upside)
Blogger Sentiment
Bullish
COR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 385.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.47%
12-Months-Change
Fundamentals
Return on Equity
144.31%
Trailing 12-Months
Asset Growth
14.14%
Trailing 12-Months
Company Description
Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
COR Company Deck
COR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cencora reported strong financial performance for fiscal 2025 with significant growth in operating income and EPS. The company raised its long-term guidance and made substantial investments in infrastructure to support future growth. Challenges were noted in the PharmaLex business, resulting in a significant goodwill impairment. However, the overall sentiment is positive due to the strong performance and strategic positioning in the specialty market.View all COR earnings summariesCOR Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
COR Stock 12 Month Forecast
Average Price Target
$393.78
▲(6.85% Upside)
Technical Analysis
Ownership Overview
6.79% Insiders
28.14% Mutual Funds
10.70% Other Institutional Investors
28.78% Public Companies and Individual Investors
Options Prices
Currently, No data available
---